• The company’s drug candidate DNX-2401 in combination with Pembrolizumab depicted clinical benefit in brain tumors like Recurrent Glioblastoma.
   
• Study data showed interim median overall survival duration of more than a year.

DNAtrix, Inc., a clinical stage, privately held biopharmaceutical firm that focuses on oncolytic virus immunotherapies to treat cancers, reportedly presented updated efficacy and safety results from its Phase 2 fully-enrolled CAPTIVE / KEYNOTE-192 DNX-2401 study during the 2019 SNO Meeting.

The study focused on assessing the efficacies of DNX-2401 (tasadenoturev), a oncolytic adenovirus developed by DNAtrix, followed by pembrolizumab in patients suffering from recurrent glioblastoma.

The outcomes showcased that the therapy evokes a durable clinical activity while also having a favorable safety profile. Positive study outcomes were presented at the 2019 SNO (Society for Neuro-Oncology) Annual Meeting that was held between November 22-24 in Phoenix, Arizona.

Overall, 48 patients suffering from recurrent glioblastoma were treated across 15 participating clinical facilities with the DNX-2401 regimen, followed by pembrolizumab. Following the treatment, a majority of the patients witnessed clinical benefits, including durable partial and complete responses.

The interim medial overall survival duration for patients is presently 12.3 months. Additionally, the interim safety analysis showcases that the treatment has a favorable benefit-risk profile. No unanticipated adverse events were recorded, and patients stayed on pembrolizumab for over 5.5 months with 34 cycles.

Presenting author of the Phase 2 study, Clark Chen, MD, PhD, stated that the positive data possesses great promise for individuals affected by glioblastoma, a commonly occurring adult brain cancer form. The disease is associated with uniform fatality and the outcomes are striking in that context.

Dr. Chen further added, the data suggests that the DNX-2401 and pembrolizumab combination could potentially revolutionize glioblastoma patient care. The company looks forward to conducting thorough studies that are focused at validating the overall efficacy of DNX-2401.

The CEO of DNAtrix, Frank Tufaro, PhD, stated that the interim data from the company’s CAPTIVE study is a significant milestone for DNAtrix to develop DNX-2401 as a novel, innovative glioblastoma treatment.

Source credit: https://www.dnatrix.com/view.cfm/123/2019-press-release